A computer-based cognitive training program called Cogmed can improve working memory and cognition and increase the attention span of children and adolescents with fragile X syndrome, according to a clinical trial. Findings from the trial were published in the study, “Cognitive training for children and adolescents with fragile…
News
CRISPR-Gold, Using Non-viral Carrier, Edits Fragile X Gene in Mice to Ease Exaggerated Behaviors
A newly developed version of the gene editing technology CRISPR — a non-viral delivery system called CRISPR-Gold — can effectively edit an autism-associated gene in a mouse model of fragile X, reducing the exaggerated repetitive behaviors common with the disorder. The study, “Nanoparticle delivery of CRISPR…
Mindfulness Program Run on App May Help Ease Stress in Women with Fragile X Children, Study Says
A mindfulness program run on a free mobile app may be a feasible way of easing stress in mothers of children with fragile X syndrome (FXS), especially the many who carry the disease-causing mutation passed on to their child, a study reports.
Implementing behavioral treatment via telehealth is a feasible and potentially cost-effective strategy for treating behavioral problems in boys with fragile X syndrome, a study shows. This strategy is able to circumvent the problem parents face when living in a rural area and cannot drive long distances to reach the nearest…
Patient’s Age, Family Income are Factors for Accessing Healthcare, FXS Caregivers Survey Reveals
Caregivers of younger children with fragile X syndrome (FXS), and those with lower family incomes, report more difficulties in accessing specialized healthcare in the U.S., a recent study found. Moreover, nearly 40% of the caregivers surveyed think their child’s doctor is…
Green Tea Compound Significantly Improves Cognitive Function in Fragile X Patients, Study Finds
Treatment with a compound found in green tea leaves significantly improved cognitive function in patients with fragile X syndrome, a study shows. This new clinical data came from a study of the epigallocatechin-3-gallate (EGCG) compound, a major component of green tea leaves. The study, “A phase 1, randomized…
Increased social avoidance during infancy and early childhood in boys with fragile X syndrome (FXS) is associated with higher risk of autism spectrum disorder (ASD) and lower risk of attention deficit/hyperactivity disorder (ADHD) and anxiety, according to a recent study. The study, “Infant Social Avoidance Predicts Autism but…
Pediatricians might not be aware of guidelines for genetic testing in children with global developmental delay (GDD), even though they often order such tests. This suggests the need for doctors to receive up-to-date training on genetic testing for GDD, especially as new tests are developed. The study with those findings, “…
Mavoglurant (AFQ056), a candidate for the treatment of fragile X syndrome (FXS), restored functionality in sensory networks but failed to do so in a cognition-related brain region in a mouse model of the disease, recent study shows. The research, “Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional…
Young adults with fragile X syndrome (FXS) and their parents have identified several areas of major concern, including those related to physical, psychological, social, and financial issues, in a qualitative study. The study, “Growing up with Fragile X Syndrome: Concerns and Care Needs of Young Adult Patients and Their…
Recent Posts
- Study highlights demands of caregiving in fragile X syndrome
- Experimental therapy improves behavior, cognition in fragile X mice
- Advocates aim to answer the question ‘Fragile what?’ this awareness month
- Fragile X drug zatolmilast misses main goal in Phase 3 trials
- Targeting star-shaped brain cells reduces fragile X seizures in mice: Study
- Marvel planning trial to test fragile X treatment in healthy volunteers
- FRAXA backs upcoming Phase 2b trial of SPG601 for fragile X syndrome
- Daily use of diabetes drug metformin eases hyperactivity in fragile X boys
- USC researchers net $6.3M federal grant to study fragile X mutations
- 1st patient enrolled in Phase 2 trial of treatment for fragile X syndrome